OncoSec Medical Incorporated

Symbol: ONCS

NASDAQ

0.2772

USD

Market price today

  • -0.0457

    P/E Ratio

  • -0.0010

    PEG Ratio

  • 1.65M

    MRK Cap

  • 0.00%

    DIV Yield

OncoSec Medical Incorporated (ONCS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-1.77%

Return on Equity

4.85%

Return on Capital Employed

-9.13%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Robert H. Arch Ph.D.
Full-time employees:40
City:Pennington
Address:24 North Main Street
IPO:2011-04-08
CIK:0001444307

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Return on Investments

The company's asset efficiency, represented by a robust -1.767% return, is a testament to OncoSec Medical Incorporated's adeptness in optimizing resource deployment. OncoSec Medical Incorporated's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 4.845%. Furthermore, the proficiency of OncoSec Medical Incorporated in capital utilization is underscored by a remarkable -9.128% return on capital employed.

Stock Prices

OncoSec Medical Incorporated's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.469, while its low point bottomed out at $0.4343. This variance in figures offers investors a lucid insight into the roller-coaster ride that is OncoSec Medical Incorporated's stock market.

Liquidity Ratios

Analyzing ONCS liquidity ratios reveals its financial health of the firm. The current ratio of 89.08% gauges short-term asset coverage for liabilities. The quick ratio (50.94%) assesses immediate liquidity, while the cash ratio (50.94%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio89.08%
Quick Ratio50.94%
Cash Ratio50.94%

Profitability Ratios

The effective tax rate stands at -5.08%, revealing its tax efficiency. The net income per EBT, 105.08%, and the EBT per EBIT, 99.66%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate-5.08%
Net Income per EBT105.08%
EBT per EBIT99.66%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.89, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding51

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -4.92, and free cash flow per share, -4.92, depict cash generation on a per-share basis. The cash per share value, 1.42, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share-4.92
Free Cash Flow per Share-4.92
Cash per Share1.42
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-3.68
Short Term Coverage Ratio-9.52

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 39.05%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.63, we discern the balance between debt and equity financing. The long-term debt to capitalization, -63.29%, and total debt to capitalization, -171.31%, ratios shed light on its capital structure. An interest coverage of -335.42 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio39.05%
Debt Equity Ratio-0.63
Long Term Debt to Capitalization-63.29%
Total Debt to Capitalization-171.31%
Interest Coverage-335.42
Cash Flow to Debt Ratio-3.68
Company Equity Multiplier-1.62

Per Share Data

Net income per share, -19.13, reflects the portion of profit attributed to each share. The book value per share, 3.42, represents the net asset value distributed per share, while the tangible book value per share, 3.21, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-19.13
Book Value Per Share3.42
Tangible Book Value Per Share3.21
Shareholders Equity Per Share3.42
Interest Debt Per Share3.47
Capex Per Share-0.14

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 23,133,111.678, captures the company's total value, considering both debt and equity. Income quality, 0.94, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 1.73%, indicates the value of non-physical assets, and capex to operating cash flow, 0.76%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value23,133,111.678
Income Quality0.94
Intangibles to Total Assets1.73%
Capex to Operating Cash Flow0.76%
Capex to Depreciation-22.96%
Graham Number38.40
Return on Tangible Assets-158.98%
Graham Net Net-1.94
Working Capital8,599,143
Tangible Asset Value5,739,875
Net Current Asset Value-527,493
Invested Capital1
ROIC-192.36%
ROE-5.59%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.13, and the price to book ratio, -0.13, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.13, and price to operating cash flows, -0.06, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-0.13
Price to Book Ratio-0.13
Price Cash Flow Ratio-0.06
Enterprise Value Multiple-0.13
Price Fair Value-0.13
Price to Operating Cash Flow Ratio-0.06
Price to Free Cash Flows Ratio-0.13
Price to Tangible Book Ratio4.78
Enterprise Value Over EBITDA-0.64
EV to Operating Cash Flow-0.72
Earnings Yield-116.82%
Free Cash Flow Yield-110.68%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of OncoSec Medical Incorporated (ONCS) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.046 in 2024.

What is the ticker symbol of OncoSec Medical Incorporated stock?

The ticker symbol of OncoSec Medical Incorporated stock is ONCS.

What is company IPO date?

IPO date of OncoSec Medical Incorporated is 2011-04-08.

What is company current share price?

Current share price is 0.277 USD.

What is stock market cap today?

The market cap of stock today is 1652822.000.

What is PEG ratio in 2024?

The current -0.001 is -0.001 in 2024.

What is the number of employees in 2024?

In 2024 the company has 40.